Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for bioMérieux in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $107.90.
Current Consensus is
The current consensus among 5 contributing investment analysts is to hold stock in bioMérieux. This rating has held steady since November 2020, when it changed from a Buy consensus rating.
bioMÃ©rieux S.A. develops and produces in vitro diagnostic solutions for private and hospital laboratories for the diagnosis of infectious diseases. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. The company was formerly known as B-D MÃ©rieux. bioMÃ©rieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMÃ©rieux S.A. is a subsidiary of Institut MÃ©rieux SA.